Sage Therapeutic (SAGE) - News Mentions

Sign up to add (SAGE) to your portfolio and access more historical data.

00%
Est. daily news mentions.

Sign up to access historical data

Sign up

Similar companies

Company News Mentions
Amgen
Amgen
AMGN		 0 100%
Gilead Sciences
Gilead Sciences
GILD		 2 0%
Catalyst Pharmaceuticals
Catalyst Pharmaceuticals
CPRX		 0 100%
Inovio Pharmaceuticals
Inovio Pharmaceuticals
INO		 0 0%
Anavex Life Sciences
Anavex Life Sciences
AVXL		 0 0%
Sage Therapeutics (SAGE) Surges 12.2%: Is This an Indication of Further Gains?
December 22
Sage Therapeutics, Inc.(NasdaqGM: SAGE) dropped from S&P Biotechnology Select Industry Index
December 22
Sage Therapeutics price target lowered to $6 from $10 at Stifel
December 16
Sage Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
November 25
Sage Therapeutics price target lowered to $4 from $7 at BofA
November 21
Sage Therapeutics Drug's Failure in Huntington's 'Not Surprising,' RBC Says
November 21
Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & More
November 21
SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study
November 20
Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor in the Treatment of Cognitive Impairment Associated with Huntington's disease
November 20
After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder
November 19
Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease
November 19
Sage Therapeutics : Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE 718) in the Treatment of Cognitive Impairment Associated with Huntington's Disease Form 8 K
November 19
Warning: SAGE is at high risk of performing badly
October 31
SAGE Therapeutics Announces Strategic Reorganization Amid Executive Departures
October 31
Sage Therapeutics price target lowered to $26 from $52 at Piper Sandler
October 30
SAGE's Q3 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down
October 29

Month over Month

Est. daily news mentions.

Dec 2024 0
Nov 2024 0
Oct 2024 0
Sep 2024 0

How often is Sage Therapeutic mentioned in the news?

Sage Therapeutic was mentioned an estimated 0 times in online prominent news articles yesterday.

Analyzing News Mentions, how is Sage Therapeutic performing compared to its industry peers?

Sage Therapeutic underperforms its industry peers when it comes to News Mentions, ranking dead last.

Has there been an increase or decrease in news mentions of Sage Therapeutic in the last month?

There has been no significant change in the number of news mentions for Sage Therapeutic's compared to the last month.

Why is it important to track news mentions for Sage Therapeutic?

By monitoring mentions in the news for Sage Therapeutic, investors stay up to date on impactful events for the company, its industry and its competitors. Positive news might affect price in a positive way and negative news might affect price in a negative way. By tracking mentions over time, investors can also identify patterns, explore popularity and make informed decisions based on the evolving perception of Sage Therapeutic, ultimately improving their investment strategies.

Sign up and get more insights on Sage Therapeutic.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2025 AltIndex. All rights reserved.

Top Stocks

Trending Stocks
Trending Stocks on WallStreetBets
Trending Stocks on Reddit
Top Stocks
Top Stock Performers Today
Bottom Stock Performers Today
Best Airlines Stocks
Best Bank Stocks
Best Semiconductor Stocks
Best Energy Stocks
Best Fintech Stocks
Best Robotics Stocks
Best Insurance Stocks

Our Data

Datasets
Stock alerts
AI Stock Picks
AI Stock Picks - Results
Fear & Greed Index
Meme Stocks
Threads Users
Stock Predictor
Stock Picking Reviews
Stock Trading Signals
House & Congress Trading
Earnings Calendar
Index

AltIndex

News
Pricing
Sign up
Log in
API
Journalist Access
Data Disclaimer
Contact